UBS rates ROCHE HOLDINGS AG as 'Buy'
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Roche with a price target of CHF 314. Ahead of the Swiss pharmaceutical day on September 22, analyst Matthew Weston focused on the development pipeline on Wednesday evening, focusing on mid-stage drugs. He pushed back some expectations regarding market readiness, especially for some drugs that are close to Phase III. Weston did not change its estimates for 2025, but cut its pharmaceutical sales forecasts for 2026 to 2030 by an average of half a percent and its core EPS forecasts by 0.9 percent./rob/ag/la Publication of the original study: September 3, 2025 / 3:12 p.m. / GMT First distribution of the original study: September 3, 2025 / Time not specified in study / Time zone not specified in study Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html. ISIN: CH0012032048
© 2025 dpa-AFX-Analyser
Solar industry on the brink of a mega comeback?
For a long time, solar stocks were considered darlings of the stock market, but then came a sharp crash: interest rate shocks, overcapacities in China, and a price collapse that put even market leaders like SMA Solar, Enphase Energy, and SolarEdge under massive pressure. Many investors have long since turned their backs on the industry. But this could be precisely the opportunity now!
The combination of AI explosion and energy transition brings the industry back into the spotlight:
- Data centers consume megawatts – solar power offers the cheapest price per kilowatt hour
- Modern modules deliver efficiencies like nuclear power plants
- hina curbs price dumping & massively pushes expansion
This offer is only valid for a short time – so don’t hesitate, secure it now!
nachrichten-aktien-europa
